76532-35-9 Usage
Uses
Used in Pharmaceutical Industry:
1-(4-methoxynaphthalen-1-yl)-N-methylmethanamine is used as a potential treatment for attention deficit hyperactivity disorder (ADHD) due to its ability to increase dopamine levels in the brain, which can help improve focus and reduce hyperactivity in affected individuals.
Used in Research:
1-(4-methoxynaphthalen-1-yl)-N-methylmethanamine is used as a research compound for studying the effects of dopamine reuptake inhibition on various neurological and psychiatric conditions. It can provide valuable insights into the role of dopamine in the brain and the potential for developing new treatments for related disorders.
Used in Drug Abuse and Neurotoxicity Studies:
1-(4-methoxynaphthalen-1-yl)-N-methylmethanamine is used in research to investigate its abuse potential and neurotoxic effects. Understanding the risks associated with its use can help in developing strategies to prevent misuse and mitigate potential health risks.
Check Digit Verification of cas no
The CAS Registry Mumber 76532-35-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,6,5,3 and 2 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 76532-35:
(7*7)+(6*6)+(5*5)+(4*3)+(3*2)+(2*3)+(1*5)=139
139 % 10 = 9
So 76532-35-9 is a valid CAS Registry Number.
76532-35-9Relevant academic research and scientific papers
Folate Antagonists. 18. Synthesis and Antimalarial Effects of N6-(Arylmethyl)-N6-methyl-2,4,6-pteridinetriamines and Related N6,N6-Disubstituted 2,4,6-Pteridinetriamines
Elslager, Edward F.,Johnson, Judith L.,Werbel, Leslie M.
, p. 140 - 145 (2007/10/02)
N6-(Arylmethyl)-N6-methyl-2,4,6-pteridinetriamines (1-5) and related N6-substituted 2,4,6-pteridinetriamines (16-20) were obtained by the condensation of 6-chloro-2,4-pteridinediamine with methylarylmethanamine and other selected secondary amines.The requisite N-methylarylmethanamines (21-32) were prepared by the hydrogenation over Pt/C of the corresponding arylcarboxaldehyde in the presence of methanamine.Several of the N6-(arylmethyl)-N6-methyl-2,4,6-pteridinetriamines exhibited exceptional suppressive antimalarial activity against a drug-sensitive line of Plasmodium berghei in mice.N6-Methyl-N6-(1-naphthalenylmethyl)-2,4,6-pteridinetriamine (9), the most active of those compounds, was also shown to be curative at 3.16 mg/kg in a single oral dose against P. cynomolgi in the rhesus monkey.This compound was also shown to be effective against a chloroquine-resistant line of P. berghei in the mouse but showed cross-resistance to a pyrimethamine-resistant strain.Most of the 2,4,6-pteridinetriamines showed strong antibacterial action against Streptococcus faecalis and Staphylococcus aureus.
